IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 276-300 out of 1249.

<< < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>

Public Release: 25-Sep-2014
Cell Reports
NYU Langone scientists identify key factor that maintains stem cell identity
A protein implicated in several cancers appears to play a pivotal role in keeping stem cells in an immature 'pluripotent' state, according to a new study by NYU Langone Medical Center scientists.
New York Stem Cell Foundation, Lady Tata Memorial Trust for Leukemia, American Society of Hematology, Leukemia & Lymphoma Society, NIH/National Cancer Institute, National Institutes of Health

Contact: Jim Mandler
Jim.Mandler@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine

Public Release: 25-Sep-2014
Cell Reports
Novel compound prevents metastasis of multiple myeloma in mouse studies
Dana-Farber scientists and colleagues find the compound olaptesed pegol can stop multiple myeloma from spreading in mouse models, potentially leading to a new approach in addressing the challenge of metastasis, one of the deadliest aspects of cancer.
NIH/National Cancer Institue

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 25-Sep-2014
Cell
Modified vitamin D shows promise as treatment for pancreatic cancer
Salk scientists find that a vitamin D-derivative makes tumors vulnerable to chemotherapy.

Contact: Salk Communications
press@salk.edu
Salk Institute

Public Release: 25-Sep-2014
Cancer Discovery
Calming down immune cells could hold key to melanoma treatment
Immune cells may be responsible for drug resistance in melanoma patients, according to research published in Cancer Discovery.
Cancer Research UK

Contact: Greg Jones
greg.jones@cancer.org.uk
44-020-346-98311
Cancer Research UK

Public Release: 25-Sep-2014
Cell Reports
New protein players found in key disease-related metabolic pathway
Cells rely on the mechanistic target of rapamycin complex 1 (mTORC1) pathway -- which senses the availability of nutrients -- to coordinate their growth with existing environmental conditions. The lab of Whitehead Member David Sabatini has identified a family of proteins that negatively regulate the branch upstream of mTORC1 that senses amino acids, the building blocks of proteins. The mTORC1 pathway is known to be deregulated in a variety of diseases, including diabetes, epilepsy, and cancer.
National Institutes of Health, Department of Defense

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research

Public Release: 24-Sep-2014
Annals of Surgical Oncology
Most breast cancer patients who had healthy breast removed at peace with decision
More women with cancer in one breast are opting to have both breasts removed to reduce their risk of future cancer. New research shows that in the long term, most have no regrets. Mayo Clinic surveyed hundreds of women with breast cancer who had double mastectomies between 1960 and 1993 and found that nearly all would make the same choice again. The findings are published in the journal Annals of Surgical Oncology.

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 24-Sep-2014
BMJ Open
Skirt size increase linked to 33 percent greater postmenopausal breast cancer risk
Going up a skirt size over a period of 10 years between your mid 20s and mid 50s is linked to a 33 percent greater risk of developing breast cancer after the menopause, finds a large observational study published in the online journal BMJ Open.

Contact: Emma Dickinson
edickinson@bmj.com
44-020-739-36529
BMJ-British Medical Journal

Public Release: 24-Sep-2014
Journal of Clinical Oncology
Good news for young patients with a leukemia subtype associated with a poor prognosis
St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia subtype associated with a poor outcome.
NIH/National Cancer Institute, NAtional Institutes of Health, National Health & Medical Research Council, Australia, Leukemia & Lymphoma Society, Alex's Lemonade Stand Foundation, Stand Up to Cancer, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 24-Sep-2014
Journal of Clinical Investigation
Wound healing response promotes breast cancer metastasis in postpartum mice
A new study in the Journal of Clinical Investigation, suggests that dying tumor cells in postpartum breast tissue promote metastatic disease.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 24-Sep-2014
Organic & Biomolecular Chemistry
Scientists create new 'designer proteins' in fight against Alzheimer's and cancer
Chemists at the University of Leicester have reported a breakthrough in techniques to develop new drugs in the fight against diseases such as cancer and Alzheimer's.
Engineering and Physical Sciences research Council

Contact: Dr. Andrew Jamieson
andrew.jamieson@le.ac.uk
07-702-307-728
University of Leicester

Public Release: 24-Sep-2014
Journal of Thoracic Oncology
Less costly to screen for and treat early-stage lung than to treat late-stage lung cancer
The average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

Contact: Murry W. Wynes, PhD
Murry.Wynes@IASLC.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 24-Sep-2014
PLOS ONE
Bacterial 'communication system' could be used to stop and kill cancer cells, MU study finds
Researchers at the University of Missouri have discovered that a molecule used as a communication system by bacteria can be manipulated to prevent cancer cells from spreading.

Contact: Nathan Hurst
hurstn@missouri.edu
573-882-6217
University of Missouri-Columbia

Public Release: 24-Sep-2014
Journal of Thoracic Oncology
NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials
The recent launch of two clinical trials offer innovative study designs for patients with lung cancer.

Contact: Murry W. Wynes, Ph.D.
Murry.Wynes@IASLC.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 24-Sep-2014
Journal of Thoracic Oncology
Modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy
There were only modest acute changes in cardiac biomarkers and electrocardiograms and there were no clinically significant cardiac events in patients with high-dose radiation exposure to the heart following thoracic radiation therapy and short-term follow-up.

Contact: Murry W. Wynes, Ph.D.
Murry.Wynes@IASLC.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 24-Sep-2014
Proceedings of the National Academy of Sciences
A way to kill chemo-resistant ovarian cancer cells: Cut down its protector
Ovarian cancer is the most deadly gynecological cancer, claiming the lives of more than 50 percent of women who are diagnosed with the disease. A study involving Ottawa and Taiwan researchers, published in the influential Proceedings of the National Academy of Sciences, provides new insight into why ovarian cancer is often resistant to chemotherapy, as well as a potential way to improve its diagnosis and treatment.
Canadian Institutes of Health Research, National Science Council of Taiwan

Contact: Paddy Moore
padmoore@ohri.ca
613-737-8899 x73687
Ottawa Hospital Research Institute

Public Release: 23-Sep-2014
Computers for Biology and Medicine
New hope for beloved family pets
University of Leicester researchers work with Avacta Animal Health Ltd to develop novel system for diagnosing lymphoma in dogs.
Avacta Animal Health Ltd, East Midlands European Regional Development Fund

Contact: Professor Alexander Gorban
ag153@le.ac.uk
01-162-231-433
University of Leicester

Public Release: 23-Sep-2014
JAMA
Lung cancer test less effective in areas where infectious lung disease is more common
An analysis of 70 studies finds that use of the diagnostic imaging procedure of fludeoxyglucose F18-positron emission tomography combined with computed tomography may not reliably distinguish benign disease from lung cancer in populations with endemic (high prevalence) infectious lung disease compared with nonendemic regions, according to a study in the Sept. 24 issue of JAMA.

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
The JAMA Network Journals

Public Release: 23-Sep-2014
Cancer Research
Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer
Scientists at Virginia Commonwealth University Massey Cancer Center have demonstrated for the first time in preclinical studies that blocking the expression of a gene known as astrocyte elevated gene-1 halts the development and progression of liver cancer by regulating inflammation.
NIH/National Cancer Institute, James S. McDonnell Foundation

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 23-Sep-2014
JAMA
Study questions accuracy of lung cancer screens in some geographic regions
A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality.
Agency for Healthcare Research and Quality, National Institutes of Health, Department of Veterans Affairs

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Public Release: 23-Sep-2014
1st EORTC Cancer Survivorship Summit
European Journal of Cancer
Results of the 1st EORTC Cancer Survivorship Summit
A special issue of the European Journal of Cancer presents detailed reports on the wide range of research presented during the 1st EORTC Cancer Survivorship Summit held this past January in Brussels, Belgium.

Contact: John
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 23-Sep-2014
Journal of Women's Health
Opportunities to reduce patient burden associated with breast cancer screening
The many misperceptions about breast cancer screening options and risks, the benefits and costs of screening, and the need for new approaches and better education are discussed in a series of articles in a supplement to Journal of Women's Health.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 23-Sep-2014
OncoImmunology
New anti-cancer peptide vaccines and inhibitors developed by Ohio State Researchers
Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center. The vaccines and inhibitors are designed to target the HER-3 and IGF-1R receptors, which are over-expressed in cancers of the breast, pancreas, esophagus and colon.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 23-Sep-2014
Pediatrics
Increased knowledge of HPV vaccines does not predict a higher rate of vaccination
A year-long study of over 360 adolescents who were considered to be ideal candidates to receive the HPV vaccine showed that neither increased parental or adolescent knowledge about HPV or the vaccine resulted in higher rates of vaccination. That is, those with higher levels of knowledge were not more likely to obtain vaccination for themselves or their daughters.
Pennsylvania Department of Health, American Cancer Society

Contact: Joseph J. Diorio
jdiorio@asc.upenn.edu
215-746-1798
University of Pennsylvania Annenberg School for Communication

Public Release: 22-Sep-2014
Journal of Controlled Release
New chip promising for tumor-targeting research
Researchers have developed a chip capable of simulating a tumor's 'microenvironment' and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.
National Science Foundation, National Institutes of Health

Contact: Emil Venere
venere@purdue.edu
765-494-4709
Purdue University

Public Release: 22-Sep-2014
Cell Reports
Massachusetts General study reveals gene expression patterns in pancreatic CTCs
Analysis of circulating tumor cells in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases. The Massachusetts General Hospital Cancer Center investigators identified several different classes of pancreatic CTCs and found unexpected factors that may prove to be targets for improved treatment of the deadly tumor.
Stand Up to Cancer, Howard Hughes Medical Institute, Burroughs Wellcome Fund, NIH/National Institute of Biomedical Imaging and Bioengineering, NIH/National Cancer Institute, Affymetrix, Inc.

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Showing releases 276-300 out of 1249.

<< < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>

  Search News Releases

     

 

EurekAlert!